Medite Cancer Diagnostics, Inc.
MDIT
$0.00
$0.000.00%
| 09/30/2018 | 06/30/2018 | 03/31/2018 | 12/31/2017 | 09/30/2017 | |
|---|---|---|---|---|---|
| Net Income | 54.21% | 65.35% | -46.81% | -154.21% | -424.51% |
| Total Depreciation and Amortization | -43.64% | 25.93% | 44.90% | 33.33% | 107.55% |
| Total Amortization of Deferred Charges | 4,314.29% | -- | -- | 222.12% | -94.96% |
| Total Other Non-Cash Items | -87.90% | -74.07% | -85.12% | -72.84% | 780.39% |
| Change in Net Operating Assets | -173.60% | -220.54% | -1,792.86% | -11.52% | 390.99% |
| Cash from Operations | -77.32% | -35.88% | -154.42% | -3,597.96% | -16.33% |
| Capital Expenditure | 31.25% | 81.82% | 87.50% | -1.11% | 27.27% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 31.25% | 81.82% | 87.50% | 22.88% | -114.55% |
| Total Debt Issued | -80.08% | 11,725.00% | 18,200.00% | 1,189.66% | 19,554.17% |
| Total Debt Repaid | 98.81% | 72.26% | 81.15% | -4,800.00% | -21,658.33% |
| Issuance of Common Stock | -- | -- | -- | -57.20% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -582.85% | -- |
| Cash from Financing | -62.18% | 15.95% | 56.24% | -153.95% | 6,702.78% |
| Foreign Exchange rate Adjustments | 99.23% | -126.12% | 69.57% | 290.09% | -223.70% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -96.03% | -217.02% | -250.93% | -2,180.26% | 1,548.67% |
